(P124) Dosimetric Comparison of Three-Dimensional Conformal Proton Radiotherapy and Intensity-Modulated Proton Therapy for Treatment of Pediatric Hodgkin Lymphoma

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In pediatric patients with intrathoracic involvement, IMPT produced significantly lower doses to the lung and heart compared with 3DPRT. Additional studies will be needed to determine the clinical benefit of these findings.

Jamie M. Pinckard, BS, William W. Chance, MD, Cody N. Crawford, CMD, Shengpeng Jiang, Xiaodong Zhang, PhD, Anita Mahajan, MD; UT Health Science Center, San Antonio; UT MD Anderson Cancer Center

OBJECTIVES: Thoracic irradiation in pediatric patients is associated with serious long-term adverse effects. We compared the target coverage and dose distribution in normal tissues in pediatric patients with Hodgkin lymphoma using three-dimensional conformal proton radiotherapy (3DPRT) and intensity-modulated proton therapy (IMPT).

METHODS: From 2009–2014, seven pediatric patients with Hodgkin lymphoma with intrathoracic involvement received proton therapy to 21–25.2 Cobalt Gray Equivalents (CGE) in 15 fractions. Five patients received 3DPRT, and two patients received IMPT. To compare dosimetric endpoints between the modalities, an additional 3DPRT or IMPT plan was generated for each patient (n = 14 plans). Mean doses to target and nontarget tissues were then compared between 3DPRT and IMPT using the Wilcoxon matched-pair signed-rank test.

RESULTS: The planning target volume was adequately treated using both techniques. When compared to 3DPRT, IMPT resulted in a lower mean total lung dose (632 cGy vs 737 cGy; P < .05) and mean heart dose (797 cGy vs 972 cGy; P < .05). The mean dose to the breasts, thyroid gland, esophagus, pancreas, stomach, and liver were similar between the modalities.

CONCLUSIONS: In pediatric patients with intrathoracic involvement, IMPT produced significantly lower doses to the lung and heart compared with 3DPRT. Additional studies will be needed to determine the clinical benefit of these findings.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Related Content